Benefits
Promotes Relaxation Without Sedation
In a crossover trial, a single 200 mg dose of a branded l-theanine (AlphaWave) increased frontal alpha brain wave activity (p<=0.050) and whole-scalp alpha activity (p<=0.048) versus placebo in healthy adults under moderate stress. Alpha activity is a brain measurement rather than a clinical outcome, the trial was industry-funded, and its abstract does not state how many people took part.
Stress and Anxiety: Improved in Healthy Adults, Not in Diagnosed Anxiety Disorder
In 30 healthy adults, 200 mg/day for 4 weeks lowered trait anxiety on the STAI (p=0.006). In 30 healthy adults with moderate stress, 400 mg/day of a branded l-theanine lowered perceived stress at 28 days (p=0.04), but the same scale at 14 days was not significant (p=0.051) and salivary cortisol showed no significant difference between groups. In the one trial run in people diagnosed with generalized anxiety disorder, all of whom were already on antidepressant treatment, l-theanine was not significantly better than placebo on the primary anxiety measure (HAM-A, p=0.73). The GABA and serotonin explanation is a proposed mechanism, not a result measured in these trials.
Improves Focus and Attention
In 30 healthy adults taking 200 mg/day for 4 weeks, verbal fluency (p=0.001) and executive function (p=0.031) improved versus placebo. In Japanese adults aged 50 to 69, Stroop reaction time, working memory and omission errors improved. No study cited on this page gave l-theanine together with caffeine, so the popular caffeine pairing is not backed by these references.
Enhances Sleep Quality
In 30 healthy adults, 200 mg/day for 4 weeks improved PSQI sleep quality scores (p=0.013). In 98 boys aged 8 to 12 with diagnosed ADHD, some of them also on stimulant medication, 400 mg/day for 6 weeks improved sleep percentage and sleep efficiency, but sleep latency and the other sleep measures were not significant. Faster sleep onset is therefore not supported here, and in the generalized anxiety trial the Insomnia Severity Index was also not significant (p=0.35).
Supports Cognitive Function
The cognitive results actually measured on this page are verbal fluency, executive function, Stroop reaction time and working memory, in small trials of healthy adults. Protection of neurons from oxidative stress and modulation of glutamate are proposed mechanisms, not results from these trials. No study cited here measured oxidative stress, glutamate or neuronal damage in people.
Mood Improvement
In 30 healthy adults, 200 mg/day for 4 weeks lowered scores on a self-rated depression scale (p=0.019). The only trial in people diagnosed with major depressive disorder added L-theanine to sertraline 100 mg/day, so it says nothing about L-theanine used on its own and nothing about managing a mood disorder without medical care. The serotonin and dopamine explanation is a proposed mechanism, not something these trials measured.
Cardiovascular Effects: Not Measured in the Studies Cited Here
No reference cited on this page measured blood pressure, heart rate or any other cardiovascular outcome, and this page carries no cardiovascular category. Any blood pressure or heart rate claim should be treated as unsupported by these references.
Immune Effects: Not Measured in the Studies Cited Here
No reference cited on this page measured immune function, inflammatory markers or glutathione, and this page carries no immune category. Any immune or antioxidant claim should be treated as unsupported by these references.
Mechanism of action
Promotes Alpha Brain Wave Activity
L-Theanine crosses the blood-brain barrier and increases alpha brain wave activity, inducing a relaxed yet alert mental state without sedation.
Modulates Neurotransmitters
It enhances levels of GABA, serotonin, and dopamine by inhibiting excitatory neurotransmitters like glutamate, promoting relaxation and reducing stress.
Reduces Glutamate Excitotoxicity
L-Theanine binds to glutamate receptors, reducing excitotoxicity and protecting neurons from damage, which may support cognitive health.
Synergizes with Caffeine
Proposed mechanism: with caffeine, L-theanine is thought to act on dopamine and adenosine signaling. None of the trials cited on this page gave L-theanine with caffeine, so this combination is untested by these references.
Lowers Stress Response
A proposed mechanism, and the cortisol data are mixed. A single 200 mg dose blunted the salivary cortisol response to an acute stressor (p<0.001), while the 28-day trial found no significant difference in salivary cortisol between groups. Heart rate and blood pressure were not measured in any study cited here.
Improves Sleep Regulation
By increasing GABA and reducing excitatory signaling, L-Theanine promotes relaxation, facilitating faster sleep onset and better sleep quality.
Antioxidant Effects
A proposed mechanism. Glutathione, oxidative stress markers and immune outcomes were not measured in any trial cited on this page.
Anti-Inflammatory Effects
A proposed mechanism. No study cited on this page measured cytokines, inflammatory markers, immune function or cardiovascular outcomes.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 46 adults with DSM-5 generalized anxiety disorder who were already on stable antidepressant treatment, given L-theanine 450 to 900 mg/day vs placebo for 8 weeks. Outcomes: HAM-A anxiety, insomnia severity, sleep satisfaction, cognition. (J Psychiatr Res 2019, PMID 30580081)
46 adults with diagnosed generalized anxiety disorder, all on stable antidepressant treatment. 8-week intervention.
Primary endpoint negative: L-theanine did not significantly improve HAM-A anxiety scores vs placebo (p=0.73). The Insomnia Severity Index (p=0.35) and cognition were also not significant. The only gains were sleep satisfaction (p=0.015) and the Insomnia Severity Index within a subgroup that did not have clinical insomnia (p=0.007). Important honest finding — L-theanine has not held up in rigorous clinical anxiety populations as marketing might suggest. Effects in healthy individuals under acute stress are more replicable than in clinical anxiety disorders.
Double-blind, placebo-controlled crossover trial in 30 healthy Japanese adults (mean age 48.3 years) receiving L-theanine 200 mg/day vs placebo for 4 weeks. Outcomes: stress-related symptoms, sleep quality, cognitive performance. (Nutrients 2019, PMID 31623400)
30 healthy Japanese adults. Crossover.
Self-rated depression (p=0.019), trait anxiety (p=0.006) and PSQI sleep quality (p=0.013) improved vs placebo, as did verbal fluency (p=0.001) and executive function (p=0.031). This is the strongest healthy-population result on the page, but it rests on a single trial of 30 people. Generally well-tolerated.
Randomized controlled trial of L-theanine (Suntheanine®, 400 mg/day) vs placebo in 98 boys aged 8-12 with ADHD for 6 weeks. Outcomes: actigraphy-measured sleep efficiency, sleep latency. (Altern Med Rev)
98 boys with ADHD. 6-week intervention.
L-theanine modestly improved sleep percentage and sleep efficiency (about 92.4% vs 91.1% for placebo), a small effect. Sleep latency and the other actigraphy measures were not significantly different from placebo. Some participants were also taking stimulant medication. Generally well-tolerated. Note: ADHD treatment requires comprehensive evaluation; L-theanine does not replace standard ADHD therapy. Modest sleep effect in this specific pediatric population.
Randomized, triple-blind, placebo-controlled crossover trial in healthy adults with moderate stress receiving a single 200 mg dose of AlphaWave L-theanine vs placebo. The abstract does not report how many people were enrolled, so no participant number for this trial can be verified from the source. Outcomes: alpha brain wave activity and salivary cortisol after an acute stressor. (Neurol Ther 2021, PMID 34562208)
Healthy adults with moderate stress. Enrollment number not stated in the abstract.
A single dose increased frontal alpha activity (p<=0.050) and whole-scalp alpha activity (p<=0.048) and reduced the salivary cortisol response to the stressor (p<0.001) vs placebo. Single-dose crossover trial of one branded ingredient, with modest effect sizes. Industry-funded.
Randomized, double-blind, placebo-controlled trial of AlphaWave L-theanine 400 mg/day vs placebo in 30 healthy adults aged 18 to 65 with moderate stress, 15 per group, for 28 days. (Neurol Ther 2024, PMID 38758503)
30 moderately stressed adults. 28-day intervention.
Perceived Stress Scale scores improved at 28 days (p=0.04), but the same scale at 14 days was not significant (p=0.051) and salivary cortisol showed no significant difference between groups. Sleep measures (p<=0.040) and a Stroop test (p=0.005) improved. Generally safe. Only 15 people per group, and the trial was industry-funded.
Randomized, placebo-controlled trial in Japanese adults aged 50 to 69, with a single-dose test and a 12-week arm. The abstract states neither the number enrolled nor the dose, so the figures of 30 participants and 200 mg/day cannot be verified from the source. Outcomes: Stroop test, working memory, attention. (J Med Food 2021, PMID 33751906)
Japanese adults aged 50 to 69. Enrollment not stated in the abstract.
Stroop test reaction time, working memory and omission errors improved vs placebo. Because the abstract reports neither the sample size nor the dose, the size of this result and the dose that produced it cannot be checked against the source.
Randomized, double-blind, placebo-controlled trial in 60 patients with DSM-IV schizophrenia or schizoaffective disorder, 40 of whom completed, all on ongoing antipsychotic treatment, receiving L-theanine 400 mg/day vs placebo for 8 weeks. Outcomes: PANSS scales, anxiety. (J Clin Psychiatry 2011, PMID 21208586)
60 schizophrenia/schizoaffective patients.
L-theanine improved anxiety (p=0.015), PANSS positive symptoms (p=0.009), general psychopathology (p<0.001) and activation (p=0.006) vs placebo, while negative symptoms and cognition were not significant. Every participant was already on an antipsychotic. Note: niche psychiatric application; should not replace established antipsychotic therapy; adjunctive role under psychiatric supervision only.
Randomized, double-blind, placebo-controlled trial of L-theanine 200 mg/day vs placebo added to sertraline 100 mg/day in 60 patients with DSM-5 major depressive disorder, 50 of whom completed, 25 per group. Treatment ran 6 weeks, with depression scores measured at weeks 2, 4 and 6. (J Affect Disord 2023, PMID 37084960)
60 patients with major depressive disorder, 50 completed, all taking sertraline 100 mg/day.
Adding L-theanine to sertraline produced greater reductions in Hamilton depression scores at weeks 2 (p=0.02), 4 (p=0.03) and 6 (p=0.01), with higher response (p=0.05) and remission (p=0.02) rates than sertraline plus placebo. Small trial, and every participant was taking prescription sertraline, so it says nothing about L-theanine used on its own. Should not replace standard depression therapy.